Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Ipilimumab Maintenance in ED-SCLC
NCT02538666Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2015
- Primary completion
- Oct 2018
- Modality
- Monoclonal Antibodies
- Countries
- 32
01
Overview
A Phase 3 trial of nivolumab, ipilimumab in small cell lung cancer (SCLC), sponsored by Bristol Myers Squibb. Started Oct 2015; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02538666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02538666.